Expanding Medicaid under the Affordable Care Act (ACA) is associated with a reduction in overall mortality among women diagnosed with breast cancer, according to a study published January 27 in JAMA Network Open. The findings suggest the policy has delivered measurable survival benefits, though significant disparities remain across racial, ethnic, and socioeconomic groups.
The research team, led by Dr. Oluwasegun Akinyemi of Howard University in Washington, DC, found that women living in states that expanded Medicaid experienced lower mortality rates compared with those in nonexpansion states. However, the authors cautioned that insurance coverage alone does not fully address longstanding inequities in breast cancer outcomes.
“These findings support Medicaid expansion as a potentially lifesaving public health policy, particularly for women with breast cancer,” the researchers wrote. “However, the persistence of racial and ethnic disparities, especially among Black women, despite coverage expansion, suggests that insurance alone is insufficient and must be accompanied by targeted interventions.”
Medicaid expansion was designed to improve access to care and narrow health disparities, yet its impact on breast cancer mortality has remained uncertain. Prior studies have shown that social determinants of health—such as income, geography, insurance status, and systemic racism—continue to shape access to timely and high-quality breast cancer care.
To assess the policy’s effects, the Howard University team analyzed data from the National Cancer Database, examining nearly 1.6 million women aged 40 to 64 who were diagnosed with breast cancer between 2006 and 2021. Of these patients, 922,862 lived in states that expanded Medicaid early, while 672,983 resided in nonexpansion states.
The analysis found an overall 4.8% relative reduction in mortality among women in expansion states, reflected in a hazard ratio of 0.95. When examined by race and ethnicity, mortality reductions were observed among non-Hispanic White women (3.4%), non-Hispanic Black women (4.3%), and Hispanic women (19%). The associations for non-Hispanic women of other racial or ethnic groups did not reach statistical significance.
The largest survival gains were seen among women with metastatic disease, who experienced a 13.9% reduction in mortality. Additional benefits were observed among women living in the highest-income neighborhoods and those receiving immunotherapy, with mortality reductions of 9.7% and 24.1%, respectively.
The authors attributed the survival improvements to enhanced access to screening, earlier diagnosis, and more timely treatment, particularly for women from low-income and racially and ethnically diverse communities. Still, they emphasized that coverage expansion alone cannot eliminate entrenched disparities.
The study calls for further research to better understand how Medicaid expansion influences breast cancer outcomes, including its effects on adherence to guideline-recommended treatments, continuity of care, and access to high-quality oncology services. The authors also stressed the need for long-term studies to determine whether these survival benefits persist and whether additional policy measures can reduce remaining disparities among Black women and other historically marginalized groups.
